All times indicated in CET
| Thursday 24 September 2020 12:45 – 13:45 | The journey ahead: Reimagining the future of cystic fibrosis in an era of precision therapies Moderator: Isabelle Fajac, Paris, FR |
|---|---|
| 12:45 – 12:50 | Welcome and introduction -Isabelle Fajac, Paris, FR |
| 12:50 – 12:55 | The future of CF in perspective – Isabelle Fajac, Paris, FR |
| 12:55 – 13:05 | The evolving natural history of CF - Ed McKone, Dublin, IE |
| 13:05 – 13:20 | Rethinking care for an ageing community - Barry Plant, Cork, IE |
| 13:20 – 13:30 | A changing landscape in CF: challenges and opportunities to optimise care provision - Daniel Peckham, Leeds, UK |
| 13:30 – 13:45 | Panel discussion and Q&A - Isabelle Fajac, Paris, FR |
| Thursday 24 September 2020 17:45 - 18:45 | Cystic fibrosis multidisciplinary care: a holistic approach |
|---|---|
| 17:45 – 17:50 | Introduction - Nichola MacDuff, Wolverhampton, UK |
| 17:50 – 18:00 | The clinical perspective of today’s cystic fibrosis care modalities - Benedetta Fabrizzi, Ancona, IT |
| 18:00 – 18:10 | The broadened role of physiotherapy in today’s cystic fibrosis management - Hugues Gauchez, Lille, FR |
| 18:10 – 18:20 | Cystic fibrosis care and the patient, a holistic approach from the nurses’ view - Nichola MacDuff, Wolverhampton, UK |
| 18:20 – 18:30 | A patient’s view of current and future needs in cystic fibrosis care - Tim Wotton, Wimbledon, GB |
| 18:30 – 18:45 | Q&A and close - Nichola MacDuff, Wolverhampton, UK |
This is a non-promotional meeting organized and funded by F. Hoffmann-La Roche Ltd. that is intended for healthcare professionals outside of the USA. It may include scientific information about investigational compounds that are not approved or valid in your jurisdiction
| Friday 25 September 2020 07:45 - 08:45 | Current & future strategies in an evolving Cystic Fibrosis treatment landscape Moderator: Isabelle Sermet-Gaudelus, Paris, FR |
|---|---|
| 07:45 – 07:50 | Introduction Isabelle Sermet-Gaudelus, Paris, FR |
| 07:50 – 08:03 | Real-life approaches to managing P. aeruginosa infections in cystic fibrosis Carsten Schwarz, Berlin, DE |
| 08:03 – 08:16 | The future of antibiotics in an era of new therapies in cystic fibrosis Barry Plant, Cork, IE |
| 08:16 – 08:29 | In the future, what approaches can be used to address treatment burden in cystic fibrosis? Christophe Marguet, Rouen, FR |
| 08:30 – 08:45 | Q&A and closing All |
| Friday 25 September 2020 12:45 - 13:45 | The importance of Inhaled antibiotics in the age of disease modifiers |
|---|---|
| 12:45 – 12:50 | Welcome and introductions Daniel Peckham, Leeds, UK |
| 12:50 – 13:10 | Changes in microbiology and treatment after the introduction of CFTR modulators Harry Heijerman, Utrecht, the Netherlands |
| 13:10 – 13:30 | The role of inhaled antibiotics in cystic fibrosis Daniel Peckham, Leeds, UK |
| 13:30 – 13:45 | Q&A, summary and meeting close Daniel Peckham, Leeds, UK |
| Friday 25 September 2020 17:45 - 18:45 | Completing the journey for all patients Moderator: Marcus Mall, Berlin, Germany |
|---|---|
| 17:45 – 17:50 | Welcome and introduction - Marcus Mall, Berlin, DE |
| 17:50 – 18:00 | Completing the picture in cystic fibrosis (CF): challenges and opportunities Marcus Mall, Berlin, DE |
| 18:00 – 18:15 | Tuning in to the right channel – what have we learnt from CFTR? Paul Negulescu, Vertex Pharmaceuticals, San Diego, US |
| 18:15 – 18:30 | Beyond F508del: getting to all CF mutations Frederick Van Goor, Vertex Pharmaceuticals, San Diego, US |
| 18:30 – 18:45 | Panel discussion and Q&A Marcus Mall, Berlin, DE |